Pfizer, whose previous bid had already been accepted by Metsera, calls the move "reckless" and accuses Novo Nordisk of abusing its position as market leader.
Metsera, in turn, says that Novo Nordisk's offer is better than the offer from Pfizer that the company has already accepted. The pharmaceutical company is now giving Pfizer four days to adjust the offer, they write in a statement.
Metsera is dedicated to weight loss and has several drug candidates under development that both pharmaceutical giants are interested in.
Novo Nordisk's share is down 4 percent on the Copenhagen Stock Exchange today. Metsera's share is up 20 percent in American pre-market trading.
